Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Viking Therapeutics VKTX reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per ...

Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our P/B Growth Investor model based on the published ...

As Viking Therapeutics continues to advance its clinical programs, the implications for patients and investors are substantial. The promising early results from VK2735 not only signify a potential ...

That includes San Diego-based Viking Therapeutics (VKTX), a pre-revenue clinical-stage biotech company that specializes in ...